Center for Personalized Therapeutics

MONDAY, JUNE 29, 2020, 8:00-13:00 ET

8:00-9:30 ET   SESSION 1: Opening Session – Moderators: Allen Lichter, Value in Carancer Care Consortium (Vi3C), USA and Everett E. Vokes, The University of Chicago, USA

• Welcome and Introduction to Vi3C – Allen Lichter, Vi3C, USA
• KEYNOTE SPEAKER – Are cancer drug prices in the US the problem or the symptom? Clifford Hudis, American Society of Clinical Oncology, USA
• Interventional pharmacoeconomics-why and how – Daniel Goldstein, Davidoff Center, Rabin Medical Center, Israel
• Panel discussion – (moderators and speakers)

9:45-11:15 ET   SESSION 2: Proof of Concept? – Moderators: Mark Ratain, The University of Chicago, USA and Jeffrey Peppercorn, Massachusetts General Hospital, USA

• Alternative dosing of abiraterone in prostate cancer: pharmacoeconomic proof of concept- Russell Szmulewitz, The University of Chicago, USA
• Trastuzumab – Helena Earl, University of Cambridge, UK
• Ibrutinib – Varsha Gandhi, The University of Texas, MD Anderson Cancer Center, USA

11:30-13:00 ET   SESSION 3: High-Value Opportunities – Moderators: Daniel Goldstein, Davidoff Center, Rabin Medical Center, Israel and W. Douglas Figg, National Cancer Institute, USA

• Simulating alternative schedules for checkpoint inhibitors – Cody Peer, National Cancer Institute, USA
• Cost-effective treatment of multiple myeloma – Vincent Rajkumar, Mayo Clinic, USA
• Cost-effective use of tyrosine inhibitors for chronic myelogenous leukemia – Charles Schiffer, Karmanos Cancer Institute, Wayne State University, USA
• Applied clinical pharmacology in a crisis: interventional pharmacoeconomics and COVID-19 – Garth Strohbehn, University of Chicago, USA

TUESDAY, JUNE 30, 2020, 8:00-13:00 ET

8:00-9:30 ET   SESSION 4: Clinical Trial Design: Statistical Options/Challenges – Moderators: Leonard Saltz, Memorial Sloan Kettering Cancer Center, USA and Deborah Schrag, Dana-Farber Cancer Institute, USA

• Near-equivalence – a better question than non-inferiority – Ian Tannock, Princess Margaret Cancer Centre, Canada
• Bayesian non-inferiority – Gary Rosner, Johns-Hopkins University, USA
• How do we assess the value of cancer drug optimization? – Mark Sculpher, University of York, UK

9:45-11:15 ET   SESSION 5: Biosimilars and Patent Issues – Moderators: David Hyman, Georgetown University, USA and R Donald Harvey, Emory University, USA

• Clinical development of biosimilars: lessons for interventional pharmacoeconomics – Sarah Yim, CDER, FDA, USA
• Biosimilars for inflammatory bowel disease – David Rubin, University of Chicago, USA
• Are dubious patents a large or small issue? – Robin Feldman, Hastings College of the Law, University of California, USA

11:30-13:00 ET   SESSION 6: Creating the Infrastructure for Interventional Pharmacoeconomic Trials – Moderators: Ian Tannock, Princess Margaret Cancer Centre, Canada and R Donald Harvey, Emory University, USA

• A payer perspective – Peter Clark, Cancer Drug Fund, UK
• A clinician’s perspective – Amit Sanyal, SSM Health Care Center, USA
• A clinical trialist’s perspective – Matthew Seymour, University of Leeds, UK
• Opportunities in India – a perspective from a low-middle income country – CS Pramesh, Tata Memorial Hospital, India

WEDNESDAY, JULY 1, 2020, 8:00-13:00 ET

8:00-9:20 ET   SESSION 7: Opportunities to Optimize Cancer Policies – Moderators: Michael Stebbins, Science Advisors, LLC and Mark Fendrick, University of Michigan, USA

• United States of America – Blase Polite, The University of Chicago, USA
• Canada – Kelvin Chan, Sunnybrook Research Institute, Canada
• Singapore – Boon Cher Goh, National University Cancer Institute, Singapore
• Panel discussion – Panelists: Herbert Loong, The Chinese University of Hong Kong, Hong Kong, Roger von Moos, Cantonal Hospital Graubuenden, Switzerland, and Max Kanner, Office of Senator Dick Durbin, USA, plus speakers and moderators

9:35-11:05 ET     SESSION 8: The Interventional Pharmacoeconomic Toolbox – Moderators: Michael Millenson, Health Quality Advisors LLC and Raya Leibowitz, Tel Aviv University, Israel

• Payer intervention: the example of abiraterone – Vicky Brown, Humana, USA
• Inclusive shared savings: considerations for implementation – David Hyman, Georgetown University, USA
• What’s in it for patients? – Deborah Collyar, Patient Advocates in Research, USA
• Alternative dispensing and other options for pharmacists – R Donald Harvey, Emory University, USA

11:20-13:00 ET   SESSION 9: CLOSING SESSION: Focus on Optimal Dosing of Ibrutinib – Moderators: Beth Jacobson, Grand Rounds and Paul Goldberg, The Cancer Letter

• Ibrutinib’s cardiac toxicity –  Javid Moslehi, Vanderbilt University, USA
• The justification for maximizing the dose-intensity of ibrutinib – Steven Coutre, Stanford, USA
• The justification for a randomized trial of low-dose ibrutinib – Mark Ratain, The University of Chicago, USA
• Panel discussion – Panelists: Kerry Rogers, Ohio State University, USA, Chadi Nabhan, Caris Life Sciences plus all session participants
• The future of interventional pharmacoeconomics – Leonard Saltz, Memorial Sloan-Kettering Cancer Center, USA